iBio Presents Updates on IBIO-CFB03 Fibrosis Drug Candidate At 2014 Annual Shareholders Meeting
Biotechnology company iBio Inc. recently provided updates at its Annual Meeting for shareholders and attendees on the development progress of IBIO-CFB03 and its potential to address unmet medical needs for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The creator of IBIO-CFB03, Dr. Feghali-Bostwick from the Medical University…